196 related articles for article (PubMed ID: 32517333)
1.
Kuttel MM; Casadevall A; Oscarson S
Molecules; 2020 Jun; 25(11):. PubMed ID: 32517333
[TBL] [Abstract][Full Text] [Related]
2. A Glucuronoxylomannan Epitope Exhibits Serotype-Specific Accessibility and Redistributes towards the Capsule Surface during Titanization of the Fungal Pathogen Cryptococcus neoformans.
Probert M; Zhou X; Goodall M; Johnston SA; Bielska E; Ballou ER; May RC
Infect Immun; 2019 Apr; 87(4):. PubMed ID: 30670549
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans.
Brandt S; Thorkildson P; Kozel TR
Clin Diagn Lab Immunol; 2003 Sep; 10(5):903-9. PubMed ID: 12965925
[TBL] [Abstract][Full Text] [Related]
4. Capsule structural heterogeneity and antigenic variation in Cryptococcus neoformans.
McFadden DC; Fries BC; Wang F; Casadevall A
Eukaryot Cell; 2007 Aug; 6(8):1464-73. PubMed ID: 17601878
[TBL] [Abstract][Full Text] [Related]
5. Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates: implications for vaccine development.
May RJ; Beenhouwer DO; Scharff MD
J Immunol; 2003 Nov; 171(9):4905-12. PubMed ID: 14568972
[TBL] [Abstract][Full Text] [Related]
6. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
Pirofski L; Lui R; DeShaw M; Kressel AB; Zhong Z
Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223
[TBL] [Abstract][Full Text] [Related]
7. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection.
Fleuridor R; Lees A; Pirofski L
J Immunol; 2001 Jan; 166(2):1087-96. PubMed ID: 11145689
[TBL] [Abstract][Full Text] [Related]
8. The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction.
McFadden DC; De Jesus M; Casadevall A
J Biol Chem; 2006 Jan; 281(4):1868-75. PubMed ID: 16278213
[TBL] [Abstract][Full Text] [Related]
9. Unexpected diversity in the fine specificity of monoclonal antibodies that use the same V region gene to glucuronoxylomannan of Cryptococcus neoformans.
McFadden DC; Casadevall A
J Immunol; 2004 Mar; 172(6):3670-7. PubMed ID: 15004170
[TBL] [Abstract][Full Text] [Related]
10. Protein-polysaccharide interactions. A monoclonal antibody specific for the capsular polysaccharide of Cryptococcus neoformans.
Otteson EW; Welch WH; Kozel TR
J Biol Chem; 1994 Jan; 269(3):1858-64. PubMed ID: 8294434
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.
Mukherjee J; Kozel TR; Casadevall A
J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877
[TBL] [Abstract][Full Text] [Related]
12. Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains.
Kozel TR; Levitz SM; Dromer F; Gates MA; Thorkildson P; Janbon G
Infect Immun; 2003 May; 71(5):2868-75. PubMed ID: 12704160
[TBL] [Abstract][Full Text] [Related]
13. Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens.
Pirofski LA
Trends Microbiol; 2001 Sep; 9(9):445-51. PubMed ID: 11553457
[TBL] [Abstract][Full Text] [Related]
14. Synthetic Glycans Reveal Determinants of Antibody Functional Efficacy against a Fungal Pathogen.
Crawford CJ; Guazzelli L; McConnell SA; McCabe O; d'Errico C; Greengo SD; Wear MP; Jedlicka AE; Casadevall A; Oscarson S
ACS Infect Dis; 2024 Feb; 10(2):475-488. PubMed ID: 37856427
[TBL] [Abstract][Full Text] [Related]
15. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library.
Beenhouwer DO; May RJ; Valadon P; Scharff MD
J Immunol; 2002 Dec; 169(12):6992-9. PubMed ID: 12471134
[TBL] [Abstract][Full Text] [Related]
16. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.
Casadevall A; Mukherjee J; Devi SJ; Schneerson R; Robbins JB; Scharff MD
J Infect Dis; 1992 Jun; 165(6):1086-93. PubMed ID: 1583327
[TBL] [Abstract][Full Text] [Related]
17. Determination of antigen binding specificities of Cryptococcus neoformans factor sera by enzyme-linked immunosorbent assay.
Belay T; Cherniak R
Infect Immun; 1995 May; 63(5):1810-9. PubMed ID: 7537249
[TBL] [Abstract][Full Text] [Related]
18. The structure of a
Hargett AA; Azurmendi HF; Crawford CJ; Wear MP; Oscarson S; Casadevall A; Freedberg DI
Proc Natl Acad Sci U S A; 2024 Feb; 121(7):e2315733121. PubMed ID: 38330012
[No Abstract] [Full Text] [Related]
19. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody.
Zhang H; Zhong Z; Pirofski LA
Infect Immun; 1997 Apr; 65(4):1158-64. PubMed ID: 9119446
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures.
Oscarson S; Alpe M; Svahnberg P; Nakouzi A; Casadevall A
Vaccine; 2005 Jun; 23(30):3961-72. PubMed ID: 15917118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
